UNSPSC 51312106: Lodoxamide ethyl

This classification denotes a mast cell stabilizer with the molecular formula C15H14ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQY1B8145B, chemically known as acetic acid, 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)-, bis 2-oxo-, diethyl ester, but more generally known as lodoxamide ethyl, which bears US NIH Compound Identifier 40915. European Medicines Agency schedules lodoxamide ethyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08553MIG.

Most nations, for tariff purposes, schedule lodoxamide ethyl under HS 29269095. SMILES: CCOC(=O)C(=O)NC1CC(CC(C1CL)NC(=O)C(=O)OCC)C#N.

UNSPSC 51312106 Lodoxamide ethyl is a Commodity code that nominally covers a specific ophthalmic antihistamine medication, but recent state and local solicitation activity shows a material mismatch: the single posted opportunity under this code seeks naloxone and drug deactivation systems, not lodoxamide. State and local governments appear to use this code inconsistently or erroneously when tagging emergency-response pharmaceuticals and harm-reduction equipment, rather than the narrow scope the code name suggests.

Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023. This represents the only recent activity visible under the code. The mismatch between the code's nominal scope—a single pharmaceutical compound—and the actual procurement suggests either a cataloging error by the issuing body or a broader tagging practice for emergency-response medications that falls outside the code's intended use. Until additional solicitations appear, this code shows little reliable activity aligned with its stated commodity definition.